Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design Academic Article uri icon

Overview

MeSH Major

  • Adrenal Cortex Hormones
  • Adrenergic beta-2 Receptor Agonists
  • Aminopyridines
  • Benzamides
  • Bronchitis, Chronic
  • Bronchodilator Agents
  • Budesonide, Formoterol Fumarate Drug Combination
  • Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
  • Lung
  • Phosphodiesterase 4 Inhibitors
  • Pulmonary Disease, Chronic Obstructive

abstract

  • This study will further characterize the effects of roflumilast added to ICS/LABA on exacerbation rates, lung function, and health of severe-very severe COPD participants at risk of further exacerbations. The results will determine the clinical benefits of roflumilast combined with standard-of-care inhaled COPD treatment.

publication date

  • August 17, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4994799

Digital Object Identifier (DOI)

  • 10.2147/COPD.S109661

PubMed ID

  • 27574416

Additional Document Info

start page

  • 1921

end page

  • 8

volume

  • 11

number

  • 1